Therapeutic Advances in Psychopharmacology

Papers
(The TQCC of Therapeutic Advances in Psychopharmacology is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
Drug safety in older patients with alcohol use disorder: a retrospective cohort study44
Olanzapine long-acting injection, discontinuation rates and reasons for discontinuation: 10 years’ experience at a UK high-secure hospital29
Exploring the clinical factors affecting lithium dose and plasma level and the effect of brand28
Analysis of the clinical characteristics of olanzapine-induced acute pancreatitis27
Tardive dyskinesia: understanding current challenges in diagnosis and treatment26
Antipsychotic polypharmacy and clozapine prescribing patterns: evolution and correlates before and after a psychiatric hospitalisation24
Real-life effectiveness of transitioning from paliperidone palmitate 1-monthly to paliperidone palmitate 3-monthly long-acting injectable formulation24
Hypercoagulable state in patients with schizophrenia: different effects of acute and chronic antipsychotic medications23
Prevalence and predictors of inappropriate prescribing in outpatients with severe mental illness22
Risperidone-induced neuroleptic malignant syndrome: a case report21
Increased amisulpride serum concentration in a patient treated with concomitant pregabalin and trazodone: a case report19
Metformin co-commencement at time of antipsychotic initiation for attenuation of weight gain: a systematic review and meta-analysis16
Will psilocybin lose its magic in the clinical setting?16
Effect of long-acting injectable antipsychotics on hospitalizations and global functioning in schizophrenia: a naturalistic mirror-image study15
History repeating: guidelines to address common problems in psychedelic science14
Plasma levels of interleukin-6 and 3-methoxy-4-hydroxyphenylglycol and treatment with milnacipran in major depression13
Low-frequency repetitive transcranial magnetic stimulation for the treatment of post-traumatic stress disorder and its comparison with high-frequency stimulation: a systematic review and meta-analysis12
Corrigendum to ‘Comment on: History repeating: guidelines to address common problems in psychedelic science’12
Ketamine and esketamine in suicidal thoughts and behaviors: a systematic review11
Preventing and treating delirium in clinical settings for older adults10
Clozapine/norclozapine plasma level ratio and cognitive functioning in patients with schizophrenia spectrum disorders: a systematic review10
Sublingual asenapine for agitation in malabsorptive states: three patient cases10
A 6-week, phase IIb, randomized, double-blind, placebo-controlled trial of Anyu Peibo capsules for the treatment of major depressive disorder in adults9
Oral and long-acting injectable antipsychotic discontinuation and relationship to side effects in people with first episode psychosis: a longitudinal analysis of electronic health record data8
Comment on: History repeating: guidelines to address common problems in psychedelic science8
The cardiovascular safety of tricyclic antidepressants in overdose and in clinical use8
Comparative effectiveness study of paliperidone palmitate 6-month with a real-world external comparator arm of paliperidone palmitate 1-month or 3-month in patients with schizophrenia8
Management of dyslipidaemia in individuals with severe mental illness: a population-based study in the Greater Copenhagen Area7
The clinical effectiveness and cost effectiveness of clozapine for inpatients with severe borderline personality disorder (CALMED study): a randomised placebo-controlled trial7
Pathophysiology, prognosis and treatment of tardive dyskinesia6
Disrupted emotion regulation and spontaneous neural activity in panic disorder: a resting-state fMRI study6
Agomelatine for the treatment of generalized anxiety disorder: focus on its distinctive mechanism of action6
Risperidone ISM®: review and update of its usefulness in all phases of schizophrenia6
0.03528881072998